We believe VASOMAX as an oral therapy represents a therapeutic advance in the treatment of erectile dysfunction for patients seeking effective therapy for this condition," said Thomas C.

We are confident that Schering-Plough's total marketing capabilities will provide the necessary global reach to successfully promote VASOMAX to both urology specialists and primary care physicians who treat patients with male erectile dysfunction.

VASOMAX is a novel, immediate-release, oral version of phentolamine mesylate, an established alpha blocking agent.

2 million for the same period in 1996 primarily due to the clinical development of Vasomax.

In addition to Vasomax, its oral therapeutic for male erectile dysfunction (MED), the Company is developing novel fertility diagnostics and therapeutics, contraceptives and new therapeutics for benign prostatic hyperplasia, sexually transmitted diseases and prostate cancer.

A number of analysts have identified at least four drugs that may be the biggest beneficiaries of market expansion if they are eventually approved for marketing by the FDA, including three oral drugs -- Pfizer's Viagra (sildenafil), TAP Holdings' apomorphine, Zonagen's Vasomax (phentolamine) -- and Senetek's autoinjectable drug, Invicorp.

trials of Vasomax, reaffirms our beliefs regarding the prospects of Vasomax to provide a user friendly therapy for erectile dysfunction," said Joe Podolski, President and Chief Executive Officer of Zonagen, Inc.

In addition to VASOMAX, the Company is currently developing novel fertility diagnostics and therapeutics, contraceptives and new therapeutics for benign hyperplasia, sexually transmitted diseases and prostate cancer.

All content on this website, including dictionary, thesaurus, literature, geography, and other reference data is for informational purposes only. This information should not be considered complete, up to date, and is not intended to be used in place of a visit, consultation, or advice of a legal, medical, or any other professional.